Jackson Creek Investment Advisors LLC Cuts Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jackson Creek Investment Advisors LLC reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 3.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 71,749 shares of the biopharmaceutical company’s stock after selling 2,220 shares during the period. Jackson Creek Investment Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $1,497,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Rhumbline Advisers lifted its stake in Catalyst Pharmaceuticals by 0.3% during the 4th quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company’s stock worth $6,518,000 after acquiring an additional 952 shares in the last quarter. Handelsbanken Fonder AB lifted its position in shares of Catalyst Pharmaceuticals by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company’s stock worth $740,000 after purchasing an additional 1,000 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $27,000. KBC Group NV grew its holdings in shares of Catalyst Pharmaceuticals by 48.8% in the fourth quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 1,542 shares in the last quarter. Finally, Assetmark Inc. increased its stake in Catalyst Pharmaceuticals by 2.4% during the 3rd quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company’s stock worth $1,436,000 after buying an additional 1,704 shares during the period. 79.22% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CPRX has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird lifted their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a report on Monday. Truist Financial upped their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, November 11th. Bank of America reiterated a “buy” rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, Baird R W raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $32.50.

Catalyst Pharmaceuticals Stock Down 1.0 %

CPRX stock opened at $21.67 on Friday. The business has a 50 day moving average price of $22.27 and a 200 day moving average price of $21.49. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 3.31 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $24.64.

Insiders Place Their Bets

In related news, insider Brian Elsbernd sold 62,975 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company’s stock, valued at $4,333,200.72. This trade represents a 25.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steve Miller sold 50,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.